Comparative Pharmacology
Head-to-head clinical analysis: DUAVEE versus SOLTAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUAVEE versus SOLTAMOX.
DUAVEE vs SOLTAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
Selective estrogen receptor modulator (SERM). Binds to estrogen receptors, competitively inhibiting estrogen binding. In breast tissue, acts as an antagonist; in bone and cardiovascular system, acts as an agonist.
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
300 mg orally once daily for 5 days, starting on day 1 of menses.
None Documented
None Documented
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
24-36 hours in adults; prolonged in renal impairment (up to 96 hours in ESRD). Steady-state reached in ~5 days.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Primarily renal (80-90% as unchanged drug); biliary/fecal excretion accounts for 10-20%.
Category C
Category C
Selective Estrogen Receptor Modulator/Estrogen Combination
Selective Estrogen Receptor Modulator